Lifesciences

franckreporter/E+ via Getty Images Maravai Life Sciences (NASDAQ: MROV) could be worth $15 to $20 per share in a potential acquisition based on previous transactions, according to an RBC analyst, after a report that Repligen (RGEN) has…

Edwards Lifesciences (NYSE: EW) today announced that it has exercised its option to acquire an early-stage Israeli transvascular coronary angioplasty company Inovalife Biomedical IndustriesNo financial details were…

On Tuesday, Edwards Lifesciences (NYSE:), a prominent player in the medical technology field, retained its Buy rating and a price target of $100.00, as reaffirmed by a leading financial services firm. This endorsement comes amid…